Internalization and recycling of the CB1 cannabinoid receptor

被引:238
|
作者
Hsieh, C
Brown, S
Derleth, C
Mackie, K
机构
[1] Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Physiol & Biophys, Seattle, WA 98195 USA
关键词
CB1 cannabinoid receptor; tolerance; internalization; recycling; cannabimimetic drugs; receptor regulation;
D O I
10.1046/j.1471-4159.1999.0730493.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tolerance develops rapidly to cannabis, cannabinoids, and related drugs acting at the CBI cannabinoid receptor. However, little is known about what happens to the receptor as tolerance is developing. In this study, we have found that CB1 receptors are rapidly internalized following agonist binding and receptor activation. Efficacious cannabinoid agonists (WIN 55,212-2, CP 55,940, and HU 210) caused rapid internalization. Methanandamide (an analogue of an endogenous cannabinoid, anandamide) was less effective, causing internalization only at high concentration, whereas Delta(9)-tetrahydrocannabinol caused little internalization, even at 3 mu M. CB1 internalized via clathrin-coated pits as sequestration was inhibited by hypertonic sucrose. Internalization did not require activated G protein alpha(i), alpha(o), or alpha(s) subunits. A region of the extreme carboxy terminus of the receptor was necessary for internalization, as a mutant CBI receptor lacking the last 14 residues did not internalize, whereas a mutant lacking the last 10 residues did. Steps involved in the recycling of sequestered receptor were also investigated. Recovery of CB1 to the cell surface after short (20 min) but not long (90 min) agonist treatment was independent of new protein synthesis. Recycling also required endosomal acidification and dephosphorylation. These results show that CB1 receptor trafficking is dynamically regulated by cannabimimetic drugs.
引用
收藏
页码:493 / 501
页数:9
相关论文
共 50 条
  • [1] Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization
    Jin, WZ
    Brown, S
    Roche, JP
    Hsieh, C
    Celver, JP
    Kovoor, A
    Chavkin, C
    Mackie, K
    [J]. JOURNAL OF NEUROSCIENCE, 1999, 19 (10): : 3773 - 3780
  • [2] Cannabinoid CB1 Receptor Antagonists
    Thomas, Brian F.
    [J]. DRUG DEVELOPMENT RESEARCH, 2009, 70 (08) : 525 - 526
  • [3] The CB1 cannabinoid receptor in the brain
    Howlett, AC
    [J]. NEUROBIOLOGY OF DISEASE, 1998, 5 (06) : 405 - 416
  • [4] CB1 cannabinoid receptor antagonists
    Barth, F
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40, 2005, 40 : 103 - 118
  • [5] CB1 cannabinoid receptor ligands
    Thakur, GA
    Nikas, SP
    Makriyannis, A
    [J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (07) : 631 - 640
  • [6] The Cannabinoid CB1 Receptor in Schizophrenia
    Borgan, Faith
    Kokkinou, Michelle
    Howes, Oliver
    [J]. BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING, 2021, 6 (06) : 646 - 659
  • [7] Regulation of CB1 cannabinoid receptor internalization by a promiscuous phosphorylation-dependent mechanism
    Daigle, Tanya L.
    Kwok, Mary Lee
    Mackie, Ken
    [J]. JOURNAL OF NEUROCHEMISTRY, 2008, 106 (01) : 70 - 82
  • [8] Voltage dependence of the cannabinoid CB1 receptor
    Goldberger, Esty
    Tauber, Merav
    Ben-Chaim, Yair
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [9] Allosteric Modulation of Cannabinoid CB1 Receptor
    Ross, Ruth A.
    Baillie, Gemma L.
    Pertwee, Roger G.
    [J]. FASEB JOURNAL, 2012, 26
  • [10] Allosteric modulation of the cannabinoid CB1 receptor
    Price, MR
    Baillie, GL
    Thomas, A
    Stevenson, LA
    Easson, M
    Goodwin, R
    McLean, A
    McIntosh, L
    Goodwin, G
    Walker, G
    Westwood, P
    Marrs, J
    Thomson, F
    Cowley, P
    Christopoulos, A
    Pertwee, RG
    Ross, RA
    [J]. MOLECULAR PHARMACOLOGY, 2005, 68 (05) : 1484 - 1495